Masimo said that, as part of the limited market release, selected physician offices, emergency medical services, blood donation centers and hospitals in eligible countries outside of the US will be the first to use and benefit from the new point-of-care blood testing capability.

According to Masimo, the Pronto-7 is a palm-sized device used for measuring hemoglobin in less than one minute without the needles, time-consuming laboratory analysis, risk of blood contamination, hazardous medical waste, and patient discomfort associated with traditional blood tests. The Pronto-7 is also the first Masimo device to feature Rainbow 4D designed for fast and accurate spot-check SpHb measurements along with SpO2 and pulse rate even in low perfusion conditions.

The Masimo Pronto-7 with dimensions of just 13cm x 7.2cm x 2.5cm (5.1″ x 2.8″ x 1″) and weight of 296 grams (10.5 ounces) puts the power of noninvasive hemoglobin spot-check testing into any clinician’s hands in almost any environment. Because of the device’s embedded 802.11 b/g and Bluetooth communication capability, wireless printing or emailing of test results is enabled and future upgrades will allow for wireless transmission to electronic health record (EHR) systems.

Joe Kiani, founder and CEO Masimo, said: “The portable Pronto-7 device is the perfect complement to existing Masimo Rainbow devices currently used in hospitals throughout the world to help clinicians continuously assess hemoglobin, detect internal bleeding, and aid in blood transfusion management.

“We believe that the Pronto-7 will have significant appeal to clinicians whose patients don’t require continuous hemoglobin monitoring, but do appreciate the immediate and noninvasive anytime/anywhere testing capability it offers.”